Ranibizumab (anti-VEGF)

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) [1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1].

Product Specifications

CAS Number

[347396-82-1]

Product Name Alternative

RG-6321 (anti-VEGF)

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ranibizumab-anti-vegf.html

Purity

99.42

Solubility

H2O

Smiles

[Ranibizumab(anti-VEGF)]

Molecular Weight

(49.19 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Mustafa Şahiner, et al. The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture. Turk J Ophthalmol. 2018 Aug;48 (4) :190-195.|[2]K J Kim, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7 (1) :53-64.|[3]Richard Filek, et al. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019 Jul 1;13:1097-1114.